In this issue of Blood, Langerbeins et al 1 evaluate the prognostic value of the current
chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) using a pooled data …

Cytotoxic chemotherapy in combination with an anti-CD20 antibody (known as
chemoimmunotherapy) has been a widely used treatment for patients with CLL. Each …

Currently approved treatment options in this setting include continuous monotherapy with a
Bruton tyrosine kinase (BTK) inhibitor and FD venetoclax plus obinutuzumab. Preclinical …

In this issue of Blood, Langerbeins et al on behalf of the German CLL Study Group
(GCLLSG) report “positive” results of the CLL12 trial investigating the ability of ibrutinib to …

In this issue of Blood Advances, Brieghel et al 1 have demonstrated the successful
implementation of a health care model where low-risk, asymptomatic patients with chronic …

Recently, an international collaboration collected information from; 3500 chronic lymphocytic
leukemia (CLL) patients to develop a comprehensive tool for predicting overall survival …

During the the last two decades several biological prognostic markers have been identified
in chronic lymphocytic leukemia (CLL)[1]. Some, like the IGHV mutational status and TP53 …

In this issue of Blood, Gauthier and colleagues present the results of a pilot study evaluating
the safety and feasibility of administrating ibrutinib concurrently with CD3zeta, 4-1BB …

While confirming that adding rituximab to Ibr does not provide any benefit over Ibr alone, this
long-term follow-up of 547 patients with treatment-naive (TN) CLL continued to show a …

In this issue of Blood, Langerak et al report on the prognostic value of minimal residual
disease (MRD) status in elderly patients with comorbid chronic lymphocytic leukemia (CLL) …